TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04558268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone is a corticosteroid. It prevents the release of substances in the body that cause inflammation. It also suppresses the immune system.~Prednisone is used as an anti-inflammatory or an immunosuppressant medication. Prednisone treats many different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Progesterone
Description: Progesterone is a female hormone important for the regulation of ovulation and menstruation.~Progesterone is used to cause menstrual periods in women who have not yet reached menopause but are not having periods due to a lack of progesterone in the body. It is also used to prevent overgrowth in the lining of the uterus in postmenopausal women who are receiving estrogen hormone replacement therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone is a female hormone important for the regulation of ovulation and menstruation.~Progesterone is used to cause menstrual periods in women who have not yet reached menopause but are not having periods due to a lack of progesterone in the body. It is also used to prevent overgrowth in the lining of the uterus in postmenopausal women who are receiving estrogen hormone replacement therapy.
Study: NCT03155997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally.
Study: NCT00632996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Exercise, manual therapy, patient education, posture, home exercise program
Study: NCT03600870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: Midodrine is an oral alpha-1 agonist that increases vascular tone. It is administered orally. The initial starting dose will be midodrine 5mg orally three times a day. After 7-10 days, patients will increase the dose to 10mg three times a day as tolerated if no adverse effects occur. Treatment duration will be 6 months.
Study: NCT01340404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: Stem cell transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion program
Description: Transfusion program
Study: NCT03596970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC withdrawal
Description: Everolimus (RAD001) with MMF and Steroids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus with reduced TAC
Description: Active comparator arm: Everolimus (RAD001) with reduced TAC and Steroids
Study: NCT03751969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: The first 2 subjects will receive an intravenous injection of 0.4 mg/kg of HSK3486 emulsion injection (containing \[14C\] HSK3486 at a radiation dose of 5 nCi/0.4 mg/kg, i.e. a subject with the body weight of 60 kg is administered with a radiation dose of 300 nCi). The radiation dose for subsequent subjects can be adjusted based on the results of the first 2 subjects.
Study: NCT04558268

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vit D
Description: Vitamin D acts on our bones, intestines, kidneys and parathyroid glands to keep calcium in balance throughout our body. Vitamin D receptors are also located within our cardiovascular system, lungs, pancreas, skeletal muscle, skin, and reproductive organs. In summary, vitamin D is a prohormone that is essential for good health.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vit D
Description: Vitamin D acts on our bones, intestines, kidneys and parathyroid glands to keep calcium in balance throughout our body. Vitamin D receptors are also located within our cardiovascular system, lungs, pancreas, skeletal muscle, skin, and reproductive organs. In summary, vitamin D is a prohormone that is essential for good health.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Iron Supplement
Description: Iron is one of the minerals in the human body. It is one of the components of hemoglobin, the substance in red blood cells that helps blood carry oxygen throughout the body.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron Supplement
Description: Iron is one of the minerals in the human body. It is one of the components of hemoglobin, the substance in red blood cells that helps blood carry oxygen throughout the body.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: Folic acid is a type of B vitamin that is normally found in foods such as dried beans, peas, lentils, oranges, whole-wheat products, liver, asparagus, beets, broccoli, brussels sprouts, and spinach.~Folic acid helps your body produce and maintain new cells, and also helps prevent changes to DNA that may lead to cancer.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Folic acid is a type of B vitamin that is normally found in foods such as dried beans, peas, lentils, oranges, whole-wheat products, liver, asparagus, beets, broccoli, brussels sprouts, and spinach.~Folic acid helps your body produce and maintain new cells, and also helps prevent changes to DNA that may lead to cancer.
Study: NCT04414462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exergaming training
Description: * HEADING: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~* TIGHTROPE TENSION: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~* SNOWBOARD SLALOM: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~* TABLE TILT: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: training - Group II
Description: * Wobble board for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Habituation exercises for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Double leg stance with eyes open and eyes closed on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Single leg stance with eyes open and eyes open on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Tandem walk stance with eyes open and eyes closed on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.
Study: NCT03728855

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-administration of medication (SAM)
Description: Patients use medication from their own stock, self-administered.
Study: NCT05965453

Intervention type: DEVICE
Intervention: the Castor single branch stent graft
Description: Participants who received thoracic endovascular aortic repair by meant of the Castor single branch stent graft from June 2018 to June 2022 were enrolled in our study.
Study: NCT02868645

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Patients with bone fibrous dysplasia will have blood sampling to assess periostin rate in serum
Study: NCT02792660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injeq IQ-Needle
Description: Injeq IQ-Needle is a spinal needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with cerebrospinal fluid.
Study: NCT01257672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: ondansetron syrup (0,15 mg/Kg of body weight)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Domperidone
Description: domperidone syrup (0,5 mg/Kg of body weight)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02139267

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX-188E
Description: DNA vaccine administered via IM route using TDS-IM electroporation device

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX-188E
Description: DNA vaccine administered via IM route using TDS-IM electroporation device
Study: NCT03127852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medly
Study: NCT03771001

Intervention type: OTHER
Group type: OTHER
Intervention: Motivational Interviewing coaching and habit-building app
Description: Coaches will use a manualized motivational interviewing approach and participants' wellness promoting changes will be supported via a habit building app that also delivers a micro-mindfulness program
Study: NCT02123394

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients allocated to the Placebo group will be treated with detuned pulsed ultrasound therapy for 5 minutes and detuned short wave diathermy in pulsed mode for 25 minutes. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McKenzie method
Description: The patients of the McKenzie group will be treated according to the principles of the method and the choice of therapeutic intervention will be guided by the physical examination findings and classification. Patients will also receive written instructions from the Treat Your Own Back book and will be asked to perform home exercises based on the principles of McKenzie method. The description of the exercises that will be prescribed in this study are already published elsewhere. Compliance with home exercises will be monitored by means of a daily-log that the patient will fill in at home and bring to the therapist at each subsequent session. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
Study: NCT04405167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Description: Tasquinimod will be supplied as oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Description: Tasquinimod will be supplied as oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Description: Tasquinimod will be supplied as oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Description: Tasquinimod will be supplied as oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRd chemotherapy
Description: IRd chemotherapy with ixazomib, lenalidomide, and dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRd chemotherapy
Description: IRd chemotherapy with ixazomib, lenalidomide, and dexamethasone
Study: NCT02283983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mittens and booties

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cooling helmet
Study: NCT01830244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel- 125 mg/m2 days 1,8, 15 for 12 weeks
Study: NCT03304912

Intervention type: BEHAVIORAL
Intervention: PrEP Education and option to accept a PrEP prescription
Description: Participants will receive educational information about PrEP, be offered a PrEP prescription, and those who choose to initiated PrEP will be monitored for side-effects and adherence at their follow-up visit. There is no group assignment within this study and WWID do not have to choose to initiate PrEP. Rather, the goal of this study is to understand factors that impact PrEP initiation (and engagement in the PrEP care continuum).
Study: NCT03869216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Shared Decision-Making Intervention
Description: The intervention includes a web-based patients' decision aid about PSA-based prostate cancer screening, risks and preferences. The providers receive a summary of the USPSTF 2018 guidelines and main components of the Agency for Healthcare Research and Quality (AHRQ) SHARE curriculum, a link to a video of a prototypical shared decision making conversation, and a laminated shared decision making reminder card.
Study: NCT04412772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen.
Study: NCT02418728

Intervention type: OTHER
Intervention: subcutaneous adipose tissue microdialysis under local beta/alpha blockade
Description: adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis

Intervention type: OTHER
Intervention: subcutaneous adipose tissue microdialysis under local beta/alpha blockade
Description: adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis
Study: NCT01135394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 30 mg tablet once daily for 4 weeks, then increased to 45 mg once daily for an additional 8 weeks. Total dosage period is 12 weeks.
Study: NCT03968081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cyberball
Description: a ball tossing playing game in which the experimentor can control the number of throws received by the participants

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cyberball
Description: a ball tossing playing game in which the experimentor can control the number of throws received by the participants
Study: NCT01614340

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive-Behavioral Pain Self-management Program
Description: The main study intervention is training of the PTs on teams randomized into the intervention group in the evidence-based CBPSM program which has been translated for use in home health care with patients who have activity-limiting pain. The program is designed to be implemented in a manner that allows for maximal integration into routine PT care of home health patients. This will be possible because the CBPSM techniques, together with exercise and other PT techniques that constitute customary PT care, are reciprocally reinforcing. Both treatments (CBPSM and PT) encourage the use of similar behavioral and pain self-management coping skills to enhance behavioral activation, perceptions of self-efficacy, self-control, and personal mastery with regard to the management of pain.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive-Behavioral Pain Self-management Program
Description: The main study intervention is training of the PTs on teams randomized into the intervention group in the evidence-based CBPSM program which has been translated for use in home health care with patients who have activity-limiting pain. The program is designed to be implemented in a manner that allows for maximal integration into routine PT care of home health patients. This will be possible because the CBPSM techniques, together with exercise and other PT techniques that constitute customary PT care, are reciprocally reinforcing. Both treatments (CBPSM and PT) encourage the use of similar behavioral and pain self-management coping skills to enhance behavioral activation, perceptions of self-efficacy, self-control, and personal mastery with regard to the management of pain.
Study: NCT02392676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLAPARIB
Description: Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
Study: NCT03914651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 300IU rFSH Gonal-F® starting dose during controlled ovarian stimulation
Description: On menstrual cycle day 2 or day 3, 300IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of ovarian hyperstimulation syndrome（OHSS）.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150IU rFSH Gonal-F® starting dose during controlled ovarian stimulation
Description: On menstrual cycle day 2 or day 3, 150IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of OHSS or insufficient follicular growth.
Study: NCT02866903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy
Description: Intraperitoneal (IP) OXAliplatin (OXA) in association with systemic FOLFIRI bevacizumab chemotherapy Intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI (Irinotecan IV + 5-FU IV) bevacizumab chemotherapy in escalation dose (every 14 days) starting with the level 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy
Description: systemic FOLFIRI chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy
Description: bevacizumab
Study: NCT01313039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZ6244
Description: AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15
Study: NCT00639262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 200mg twice daily during XRT and 30 days after. (Sorafenib will be escalated for both cohorts to determine maximum tolerated dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 200mg twice daily during XRT and 30 days after. (Sorafenib will be escalated for both cohorts to determine maximum tolerated dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: For Cohort 2 - Gliomas only.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation Therapy (XRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation Therapy (XRT)
Study: NCT02688153

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EDWARDS INTUITY
Description: To evaluate cardiac performance characteristics and adverse events rates associated with the EDWARDS INTUITY Valve in patients undergoing AVR \& CABG.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stented aortic bioprostheses
Description: In comparison to control valves available on the market.
Study: NCT04480346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Challenging Horizons Program
Description: Intervention delivered in high schools provided by school mental health professional over the course of an academic year with twice-weekly meetings with students and 10 evening group meetings with students and 10 group sessions with parents.
Study: NCT00779363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rechargeable TANTALUS II
Description: Subjects will undergo an approximately two week baseline screening process. Eligible subjects will undergo device implantation. This will be followed by therapy initiation approximately one week after implantation. The device will then be activated to automatically deliver gastric contractility modulating (GCM) for 12 weeks of therapy. Stimulation will continue in for a safety monitoring period of 18 months following the therapy period.
Study: NCT05248529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education booklet
Description: Hip/Knee Replacement Adaptation Booklet explains preoperative preparation, post-operative care practices, how to walk with walker, what needs to be done at home after discharge
Study: NCT03224260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Oral Suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Oral Suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Oral Suspension

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matched Placebo
Description: Oral Suspension

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matched Placebo
Description: Oral Suspension

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matched Placebo
Description: Oral Suspension
Study: NCT04236219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLN-346
Description: ALLN-346 is novel urate oxidase provided as capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.
Study: NCT03654560

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HemoStyp
Description: During elective surgical procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery) subject has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical will have Hemostyp applied in accordance to instructions for use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgicel
Description: During elective surgical procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery) subject has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical will have Surgicel applied in accordance to instructions for use.
Study: NCT01789749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snare Tip Soft Coagulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Snare Tip Soft Coagulation